Morgan Stanley’s BioNexus Gene Lab BGLC Stock Holding History

Morgan Stanley’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-58	Closed	-$162	–	8100
2024 Q4	$162	Buy	+58	New	+$191	﹤0.01%	7429

Other funds holding BGLC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's BGLC Position: Q1 2025 in Review

Morgan Stanley sold out of BioNexus Gene Lab (BGLC) in Q1 2025, closing a stake of 58 shares — an estimated $162 sold.

Morgan Stanley first reported a position in BGLC in Q4 2024 and held it in 1 quarter. The position peaked at $162 in Q4 2024. 3 funds tracked by Wall St. Rank hold BGLC as of Q1 2025.

Morgan Stanley reported no remaining BioNexus Gene Lab position as of Q1 2025 after selling out during the quarter.
Morgan Stanley sold 58 BioNexus Gene Lab shares in Q1 2025, an estimated $162.
Morgan Stanley first reported a position in BioNexus Gene Lab in Q4 2024 and held it in 1 quarter.
Morgan Stanley's BioNexus Gene Lab position peaked at $162 in Q4 2024.
3 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.